Connection
David Saxon to Anti-Obesity Agents
This is a "connection" page, showing publications David Saxon has written about Anti-Obesity Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.839 |
|
|
|
-
Saxon DR, Iwamoto SJ, Mettenbrink CJ, McCormick E, Arterburn D, Daley MF, Oshiro CE, Koebnick C, Horberg M, Young DR, Bessesen DH. Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009-2015. Obesity (Silver Spring). 2019 12; 27(12):1975-1981.
Score: 0.649
-
Saxon DR, Rasouli N, Eckel RH. Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. Drugs. 2018 Feb; 78(2):203-214.
Score: 0.144
-
Kheniser K, Saxon DR, Kashyap SR. Long-Term Weight Loss Strategies for Obesity. J Clin Endocrinol Metab. 2021 06 16; 106(7):1854-1866.
Score: 0.046